CRIS jumps (65%) after showing impressive results in hematological cancers
Curis jumps after blood cancer trial indicates impressive results
May 12, 2021 11:29 AM ETCuris, Inc. (CRIS)By: Dulan Lokuwithana, SA News
Curis (CRIS +58.7%) is surging after announcing updated data from its ongoing open-label, single-arm, Phase 1/2 study of CA-4948 in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS).
As of data cut off on February 8, 2021, in 15 patients (8 MDS and 7 AML), four objective responses were recorded with signs of hematologic recovery.
The included one complete response (CR), one complete remission with incomplete hematologic recovery (CRi) with negative minimal residual disease, and two bone marrow CRs, the company said.
The two abstracts with updated data have been accepted for oral and poster presentation at the upcoming European Hematology Association 2021 Virtual Congress (EHA).
CA-4948 is an IRAK4 kinase inhibitor that is believed to be involved in toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) signaling pathways.
TLR and IL-1R pathways are frequently dysregulated in patients with AML and MDS.
Rigel Pharmaceuticals (RIGL +16.5%) is also rising in conjunction. The company has a partnership with BerGenBio for BGB324 (bemcentinib), a first-in-class selective AXL kinase inhibitor.
BGB324 is undergoing Phase 1/2 studies as a single agent for relapsed AML and MDS. and in combination with erlotinib (Tarceva) in advanced (EGFR-positive) non-small-cell lung carcinoma.
Bladerunner
